The expansive demographics and increasing research analytics on approval of newer drug manufacturing technologies is making India an attractive spot for collaboration with drug manufacturers from all over the world. The contract research segment is expected to hit 960million USD at 12% CAGR by end of 2027. The COVID-19 pandemic has catalysed clinical research and generated a scope for pharma companies in contributing through development of drugs for prevention.
This has generated the need for expert consultation often within limited time for clinical trials and research. QPS has grown from a tiny bioanalysis shop to full-fledged CRO with 1100+ employees across Europe, Asia, and USA. It is extensively working with its clients to devise strategies for a quick turnaround in the COVID-19 pandemic period.
Ben Chien, Chairman and CEO of QPS, says, “QPS strategically collaborates with the clients in their drug development process, understands the significance of each project, and manages client expectations. QPS places top priority on customer needs and customer satisfaction.”
Ben adds, “Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in neuropharmacology, DMPK, toxicology, bioanalysis, translational medicine and clinical development. An award winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities.
Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers.”
QPS is a GLP and GCP compliant CRO that has conducted over 1600 bioequivalence studies
and 50+ hospital based patient studies for market regulatory authorities like FDA, EMA, MHRA, WHO, TDP, TGA, NMPA, NPRA and GCC. Kumar Ramu, GM of QPS India says, “QPS India offers healthy population studies for generics and new drugs and has a well-designed research centre based in Hyderabad. The centre comprises 138 beds spread over 4 clinical pharmacological units to house the study participants. The QPS India Clinical Centre has 16,000+ healthy volunteers in a database and has conducted over 1,500,000 dosing. The bioanalytical unit has developed and validated 150+ bio-methods and analysed over 3,000,000 study samples using LCMS/MS. QPS India also provides backend services such as medical writing, clinical data management, statistics, quality assurance and regulatory affairs.”
Dr. Kumar Ramu, Ph.D.(Sr. Vice President & GM)
The presence of QPS in Europe, Asia and the US markets makes it a preferable partner for small-sized pharma. QPS is a mid-sized CRO with flexibility, agility and fast delivery of services which are ideal for small or medium pharma enterprises. It possesses expertise in Phase 1 to 2a study field along with 1/2a clinical trials for healthy volunteers and patients. Additionally, QPS has high specialised services includes Brain Imaging, Continuous CSF sampling, Human Mass Balance studies, Sedation studies etc. QPS have special population studies e.g. AD, PD, T2DM, Hypogonadism, obesity along with its bioanalytical services includes Data management, statistics, PK, Medical writing monitoring and consultancy services.
Dr. VVS Shiva Prasad, Ph.D, MBA. (COO, QPS India).
The Road Ahead
QPS has CLIA-certified and GLP compliant laboratories. QPS is recognised for its proven quality and is an award-winner in bioanalytic and clinical trials. Ben concludes, “Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. We are passionate about our work, creating value for patients and customers while generating opportunities for employees to thrive.”